Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18367224 | 0.90 | CYP4F2 (0.34) | CYP2C19CYP3A4CYP2C9PKMCYP4F2 | |
| SCHEMBL2473877 | 0.84 | CYP3A4 (0.37) | CYP2C19CYP3A4CYP2C9PKMCYP4F2 | |
| SCHEMBL25188768 | 0.84 | CYP4F2 (0.50) | CYP2C19CYP3A4CYP4F2CYP4A11LMNA | |
| SCHEMBL2479396 | 0.83 | CYP4F2 (0.41) | CYP2C19CYP3A4CYP2C9PKMCYP4F2 | |
| SCHEMBL18367198 | 0.83 | TSHR (0.38) | CYP2C19CYP3A4CYP2C9LMNAPOLB | |
| SCHEMBL2633828 | 0.82 | CYP4F2 (0.49) | CYP2C19CYP3A4CYP4F2CYP4A11LMNA | |
| SCHEMBL34476313 | 0.82 | CYP4F2 (0.49) | CYP2C19CYP3A4CYP4F2CYP4A11LMNA | |
| SCHEMBL356582 | 0.82 | CYP4F2 (0.34) | CYP4F2CYP4A11LMNAALDH1A1 | |
| SCHEMBL17443947 | 0.82 | USP2 (0.36) | CYP4F2CYP4A11RECQL | |
| SCHEMBL34475902 | 0.81 | CYP4F2 (0.39) | CYP4F2CYP4A11NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090509-A1 | SPIRO HETEROCYCLIC CDK2 INHIBITORS | ARCHITECT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4684837-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Temple University of the Commonwealth System of Higher Education (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250282790-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2025-09-11 | — | — | US | disclosed |
| EP-3541790-B1 | 3-(2-(4-PHENYLPIPERAZIN-1-YL)ETHYL)-2-OXA-8-AZASPIRO[4.5]DECAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS 5-HYDROXYTRYPTAMINE RECEPTOR 7 (5-HT7) MODULATORS FOR TREATING E.G. INFLAMMATORY BOWEL DISEASE, CIRCADIAN RHYTHM DISORDER OR DEPRESSION | UNIV TEMPLE (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12338247-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-06-24 | — | — | US | disclosed |
| CN-119977980-A | Novel modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025059027-A1 | CYCLOPENTA[E]PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS MALT1 INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-110177776-B | Novel modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2025-02-28 | — | — | CN | disclosed |
| US-20230112888-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2023-04-13 | — | — | US | disclosed |
| US-11319327-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2022-05-03 | — | — | US | disclosed |
| US-20110251225-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-13 | — | — | US | disclosed |
| US-20110251225-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-13 | — | — | US | disclosed |
| US-20110251225-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-13 | — | — | US | disclosed |
| EP-2373659-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010065798-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065798-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | WO | disclosed |
| US-20080058365-A1 | Fused heterocyclic compounds | AMGEN INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058365-A1 | Fused heterocyclic compounds | AMGEN INC. | 2008-03-06 | — | — | US | disclosed |
| US-7253179-B2 | Fused heterocyclic compounds | AMGEN INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253179-B2 | Fused heterocyclic compounds | AMGEN INC. (US) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282790-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR5A, HTR6 | CYP2C19 854/4885CYP3A4 1664/4885CYP2C9 2058/4885 |
| US-20110251225-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | HRH3, HRH4, HRH1 | CYP2C19 1621/4885CYP3A4 1931/4885CYP2C9 1458/4885 |
| US-20230112888-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR5A, HTR6 | CYP2C19 854/4885CYP3A4 1664/4885CYP2C9 2058/4885 |
| US-20080058365-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | CYP2C19 1437/4885CYP3A4 2070/4885CYP2C9 2974/4885 |
| US-11319327-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | HTR7, HTR6, HTR5A | CYP2C19 998/4885CYP3A4 1739/4885CYP2C9 2200/4885 |
| US-12338247-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | HTR7, HTR6, HTR5A | CYP2C19 998/4885CYP3A4 1739/4885CYP2C9 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.